A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Relative Efficacy and Tolerability of Tapentadol IR and Oxycodone IR for Acute Pain
Overview
Pharmacology
Authors
Affiliations
Objective: To evaluate the relative efficacy and tolerability of tapentadol immediate release (IR) and oxycodone IR for management of moderate to severe pain following orthopedic surgery (bunionectomy).
Methods: Randomized patients (N = 901) received oral tapentadol IR 50 or 75 mg, oxycodone HCl IR 10 mg, or placebo every 4-6 h over a 72-h period following surgery. Acetaminophen (< or =2 g) was allowed in the first 12 h after the first dose of study drug. In the primary analysis, tapentadol IR (50 and 75 mg) was evaluated for efficacy superior to placebo and non-inferior to oxycodone HCl IR 10 mg (using sum of pain intensity difference [SPID] over 48 h), and tolerability superior to oxycodone IR (using incidence of treatment-emergent adverse events [TEAEs] of nausea and/or vomiting).
Results: Statistically significantly higher mean SPID(48) values were observed with tapentadol IR (50 and 75 mg) and oxycodone HCl IR 10 mg than placebo (all p < 0.001). The efficacy of tapentadol IR 50 mg and 75 mg was non-inferior to oxycodone HCl IR 10 mg. The incidence of TEAEs of nausea and/or vomiting was statistically significantly lower with tapentadol IR 50 mg versus oxycodone IR 10 mg (35 vs. 59%; p < 0.001). No statistically significant difference in the incidence of nausea and/or vomiting was observed between tapentadol IR 75 mg and oxycodone IR 10 mg (51 vs. 59%; p = 0.057). A possible limitation of this study was that the intense dose and patient monitoring may not represent real-world situations and may result in higher incidences of TEAEs than expected in a practice setting; this bias would be similar for all treatment groups.
Conclusions: Clinically meaningful and statistically significant improvements were observed with tapentadol IR 50 mg and 75 mg compared with placebo for the relief of moderate-to-severe acute pain after orthopedic surgery. Tapentadol IR 50 mg and 75 mg were non-inferior to oxycodone HCl IR 10 mg for the treatment of acute pain based on the primary efficacy endpoint of SPID(48) and the pre-specified margin of 48 points. The incidence of nausea and/or vomiting was statistically significantly lower for tapentadol IR 50 mg and numerically lower for tapentadol IR 75 mg than for oxycodone HCl IR 10 mg.
Singla N, Rogier T, Meske D J Pain Res. 2024; 17:4399-4420.
PMID: 39723196 PMC: 11668969. DOI: 10.2147/JPR.S466723.
Kamble P, Panchal S, Prabhu R, Mohanty S, Dhotre R Cureus. 2024; 16(11):e73220.
PMID: 39651001 PMC: 11624896. DOI: 10.7759/cureus.73220.
Starcevic S, Radovanovic D, Skoric-Jokic S, Bojanic-Popovicki M, El Farra S, Mihalek N Medicina (Kaunas). 2023; 59(10).
PMID: 37893518 PMC: 10608502. DOI: 10.3390/medicina59101800.
Analgesic Efficacy and Safety of Tapentadol Immediate Release in Bunionectomy: A Meta-Analysis.
Franco-de la Torre L, Gomez-Sanchez E, Aragon-Martinez O, Hernandez-Gomez A, Franco-Gonzalez D, Guzman-Flores J Pharmaceuticals (Basel). 2023; 16(9).
PMID: 37765095 PMC: 10536393. DOI: 10.3390/ph16091287.
Prescribing trend of tapentadol in a Sydney local health district.
Mirabella J, Ravi D, Chiew A, Buckley N, Chan B Br J Clin Pharmacol. 2022; 88(9):3929-3935.
PMID: 35763675 PMC: 9544395. DOI: 10.1111/bcp.15448.